A NEW IMMUNOSUPPRESSIVE STRATEGY COMBINED WITH EARLY ANTIVIRAL THERAPY IMPROVES SURVIVAL AND LEADS TO HCV ERADICATION AT THE SAME COST OF THE HBV PROPHYLAXIS 3 YEARS AFTER LIVER TRANSPLANTATION